The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy

Cancer

Volumn 117, Issue 4, 2011, Pages 660-661

  Markman, Maurie ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

CANCER GROWTH; CANCER SURVIVAL; CLINICAL DECISION MAKING; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT PLANNING; CELL POPULATION; NOTE; OUTCOME ASSESSMENT; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS;

EID: 79551692192     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25459     Document Type: Review

References (10)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 1-6.
2. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: 3-year results. J Natl Cancer Inst. 2000; 92: 699-708.
3. Vermorken JB, Parmar MKB, Brady MF, et al. Clinical trials in ovarian carcinoma: study methodology. Ann Oncol. 2005; 16 (suppl 8): vii20-vii29.
4. Hennessy BT, Coleman RL, Markman M., Ovarian cancer. Lancet. 2009; 374: 1371-1382.
5. Rustin GJ, van der Burg E,; on behalf of MRC and EORTC Collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OVO5/EORTC 55955 trials) [abstract]. J Clin Oncol. 2009; 27 (18S): 793s. Abstract 1.
6. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24: 4699-4707.
7. Pujade-Lauraine E, Mahner S, Kaern J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) [abstract]. Gynecol Oncol. 2009; 27 (18S): 799s. Abstract LBA5509.
8. Liu PY, Alberts DS, Monk BJ, et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007; 25: 3615-3620.
9. Markman M, Webster K, Zanotti K, et al. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol. 2004; 93: 390-393.
10. Markman M, Webster K, Zanotti K, et al. Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer. Gynecol Oncol. 2004; 93: 715-717.